Daptomycin + Daptomycin
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Febrile Neutropenia
Conditions
Febrile Neutropenia
Trial Timeline
Apr 1, 2011 → Apr 1, 2013
NCT ID
NCT01216241About Daptomycin + Daptomycin
Daptomycin + Daptomycin is a phase 3 stage product being developed by Merck for Febrile Neutropenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01216241. Target conditions include Febrile Neutropenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01216241 | Phase 3 | Terminated |
| NCT00882557 | Phase 1 | Completed |
Competing Products
8 competing products in Febrile Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 85 |
| Ceftolozane-tazobactam IV | Merck | Approved | 85 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 84 |
| linezolid + vancomycin | Pfizer | Phase 3 | 76 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 22 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 74 |